Innovative diagnostics deliver reliable and actionable information, resulting in better clinical and economic health care outcomes globally.

Alere is committed to delivering high-quality products and services that patients and providers can rely on for consistently accurate and actionable information. We deploy unique innovative technologies that not only transform diagnostic products, but also expand into new platforms and solutions with proven health and economic outcomes. 

Alere i

Molecular Results in 8 Minutes

Alere i Strep A Test Kit

Faster than other molecular methods and more accurate than conventional rapid tests, the Alere™ i Strep A allows you to test and treat in one visit. 1,2

Buy Strep A Test


Now CLIA Waived

Alere i Influenza A and B Test Kit

Highly accurate, molecular results in less than 15 minutes. Rapid diagnosis of influenza can lead to reduced hospital stays, secondary complications and cost of hospital care.1,2

Buy Test Kit

How to Use the Alere i

Run the Alere™ i Influenza A & B test in any setting, from the laboratory to the physician’s office.


Alere i Molecular Point of Care Instrument

A multi-assay instrument that uses isothermal nucleic acid amplification technology to yield high sensitivity and specificity.

Buy Alere i Analyzer

Alere-I Flu Technology

Learn more about the isothermal nucleic acid amplification technology behind the Alere™ i Influenza A&B rapid test.


Alere i Influenza A and B Control
Swab Kit

20-pack of nasal swab for detection of influenza A and B.

Buy Control Swab Kit

Determine HIV-1/2 Ag/Ab Combo

Earlier HIV Detection

Alere Determine HIV-1/2 Ag/Ab Combo Test 

Alere Determine™ HIV-1/2 Ag/Ab Combo is a 4th generation test that has the ability to detect HIV earlier than 2nd and 3rd generation antibody-only tests.2   It can detect infection three weeks after it occurs as opposed to other tests that can only detect it after three months. This enables health care providers to diagnose HIV infection earlier allowing individuals to seek medical care sooner.

Features include:

  • CLIA waived for fingerstick whole blood
  • Requires minimal training
  • Test in three easy steps
  • Receive results in just 20 minutes
  • Test using whole blood, serum or plasma
  • Proven 99.9% overall clinical sensitivity for all sample types

Buy Determine Combo HIV


Breaking the HIV Infection Cycle
Identifying HIV infection early, during the most infectious stage, offers significant benefits, particularly in high-risk populations such as men who have sex with men and injecting drug users.

Get the Facts

Rapid detection also helps to get patients into effective care and treatment earlier.

 Individuals who are unaware of their infection are 3.5 times more likely to transmit the virus to someone else.1

By detecting HIV earlier, further transmission can be prevented during this highly infectious stage.

Shiga Toxin Quik Chek

Diagnose Sooner with Results in 30 Minutes

Alere Shiga Toxin Quik Chek

The new Alere Shiga Toxin Quik Chek™ assay is the only rapid test able to detect shiga toxin-producing E. Coli (STEC) toxins directly from fecal samples. The assay simultaneously detects and differentiates Stx1 and Stx2 toxins from STEC.

Unique Product

  • Direct detection of STEC toxins from primary fecal samples
  • Diagnosis up to 24 hours earlier than other rapid tests or traditional methods
  • Analytical Sensitivity: 0.04ng/mL Stx1 and Stx2
  • Differentiation of shiga toxins (Stx1 and Stx2)

Easy to Use

  • Utilizes the popular Techlab, Inc. QUIK CHEK format
  • Results in under 30 minutes
  • Compatible with primary fecal samples, broth, plate cultures and specimens in transport media


C. Diff Quik Chek Complete

Confirm if It's C. Diff  in 30 Minutes

Alere C. Diff  Quik Chek Complete

The Alere C. Diff Quik Chek Complete™ test is the only rapid cassette assay that simultaneously detects both glutamate dehydrogenase (GDH) antigen and toxins A & B of C. difficile in fecal specimens. The test detects C. difficile antigen, GDH, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease.  


  • Accurate: The C. Diff Quik Chek Complete test provides a final answer on up to 90% of samples in one test
  • Rapid: The test yields results in less than 30 minutes
  • Flexible: Samples may be performed in batches or individually for on demand testing
  • Convenient: The test works with any specimen consistency and with samples stored in transport media such as Cary Blair or C&S


  • The antigen portion of the C. Diff Quik Chek Complete Test detected 98.7% of the cyto-toxicity tissue culture-positive samples
  • The negative predictive value for the toxin portion compared to cyto-toxicity tissue culture was 98.1%
  • Toxin sensitivity was 87.8% compared to cyto-toxicity tissue culture
  • Toxin specificity was 99.4% compared to cyto-toxicity tissue culture
  • Kit Sizes = 25 tests or 50 tests

Buy C. Diff Quik Chek Complete

Afinion Analyzer

The Right Results, Right When You Need Them

Alere Afinion AS100 Analyzer

The Alere Afinion™ AS100 Analyzer is designed to enable simple and fast on-the-spot testing, regardless of the sample type, which may be whole blood or urine. Deliver accurate results during consultation for improved patient management.

Buy Analyzer


Alere Afinion HbA1c Test Cartridge

Alere™ Afinion™ HbA1c is the fastest point-of-care test in the market, providing results in just three minutes. Now you can obtain reliable results quickly and conveniently.

Buy HbA1c Test Cartridge


Alere Afinion ACR Cartridge

Alere™ Afinion™ ACR Cartridges provides a simple, fast and reliable point of care test for determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine, which can indicate microalbuminuria.

Buy ACR Cartridge


1.  Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children: Impact on Physician Decision Making and Cost. Infect. Med. 19(3): 109-111.

2.   Bonner, A.B. et al. (2003) Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. Pediatrics. Vol. 112 No. 2.